Blog
Liberation from Renal Replacement Therapy in Acute Kidney Injury patients: The current routine and insights into the future
The decision to stop RRT is a critical step that necessitates careful consideration of various clinical parameters. Currently, the liberation rocess is informed by changes in traditional kidney function markers, such as serum creatinine and urine output, in conjunction with the patient's clinical status.
The implementation of a novel kidney function biomarker in clinical routine
SphingoTec has discovered Proenkephalin A 119-159 (penKid), a biomarker with a strong body of evidence on its relevance and added value to the AKI diagnosis augmented by its strong performance in the clinical routine.
Using Proenkephalin A 119-159 as a novel biomarker to estimate GFR
In this interview, Prof. Peter Pickkers (Radboud University Medical Center, Nijmegen) highlights the research background on the novel kidney function biomarker Proenkephalin A 119-159, including a new formula for the glomerular filtration rate (GFR) based on this biomarker.
Current applications of precision medicine in intensive care medicine
Patients suffering from one particular disease are often treated with the same drug – independent of their age, gender, origin, or even the underlying disease mechanisms, which can vary greatly among different patients. In the field of personalized medicine, these differences are considered with the aim of providing individualized treatment to help the patient with the best possible outcome.
